Company Overview - Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative medicines for pain management, aiming to provide effective pain relief while minimizing the potential for abuse [1] Financial Performance - Collegium's Return on Invested Capital (ROIC) is 9.78%, which is higher than its Weighted Average Cost of Capital (WACC) of 6.19%, resulting in a ROIC to WACC ratio of 1.58, indicating efficient use of capital [2] - In comparison, Amphastar Pharmaceuticals has a ROIC of 7.52% and a WACC of 6.01%, leading to a ROIC to WACC ratio of 1.25, showing slightly lower efficiency than Collegium [3] - Syndax Pharmaceuticals and Enanta Pharmaceuticals report negative ROIC figures of -66.60% and -22.45%, respectively, with ROIC to WACC ratios of -10.30 and -3.52, indicating inefficiencies in capital utilization compared to Collegium [4] - Ironwood Pharmaceuticals has a ROIC of 11.39% and a WACC of 4.02%, resulting in a ROIC to WACC ratio of 2.84, making it the most efficient among the analyzed peers [5]